©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2025; 17(8): 103473
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.103473
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.103473
Colorectal cancer liver metastases: A radiologic point of view
Alfonso Reginelli, Vittorio Patanè, Salvatore Cappabianca, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Campania, Italy
Author contributions: All three authors contributed equally to the conception and development of this letter to the editor; Reginelli A conceptualized the manuscript, led the literature review, and drafted the initial version; Patanè V contributed significantly to the analysis of the literature, critically revised the manuscript for intellectual content, and assisted in refining the key messages; Cappabianca S provided substantial input on data interpretation, coordinated collaborative revisions, and ensured the overall coherence of the final version; all authors reviewed and approved the final manuscript for submission.
Conflict-of-interest statement: Authors have no conflict of interest to disclose.
Corresponding author: Vittorio Patanè, MD, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Luigi Miraglia 2, Naples 80138, Campania, Italy.
Received: November 20, 2024
Revised: February 23, 2025
Accepted: March 13, 2025
Published online: August 15, 2025
Processing time: 267 Days and 10.6 Hours
Revised: February 23, 2025
Accepted: March 13, 2025
Published online: August 15, 2025
Processing time: 267 Days and 10.6 Hours
Core Tip
Core Tip: This letter underscores the pivotal role of radiological imaging in managing colorectal liver metastases (CRLM). It details advanced imaging techniques, radiomics, artificial intelligence, and radiogenomics, illustrating how integrating imaging biomarkers with genomic and clinical data enhances detection, treatment planning, and prognostication. Such innovations pave the way for precision oncology, enabling more personalized and effective therapeutic strategies for CRLM patients.